Go Pro
→ Do NOT Buy SpaceX – Do This Instead (From Stansberry Research) (Ad)tc pixel
OTCMKTS:FSNUY

Fresenius SE & Co. Q1 2025 Earnings Report

Fresenius SE & Co. logo
$12.43 -0.03 (-0.20%)
As of 10/2/2026 03:58 PM Eastern
ProfileEarnings HistoryForecast

Fresenius SE & Co. EPS Results

Actual EPS
$0.23
Consensus EPS
$0.22
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Fresenius SE & Co. Revenue Results

Actual Revenue
$5.92 billion
Expected Revenue
$5.41 billion
Beat/Miss
Beat by +$513.12 million
YoY Revenue Growth
N/A

Fresenius SE & Co. Announcement Details

Quarter
Q1 2025
Date
5/7/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Fresenius SE & Co.'s next earnings date is estimated for Wednesday, November 4, 2026, based on past reporting schedules.

Conference Call Resources

Fresenius SE & Co. Earnings Headlines

Fresenius SE & Co. (OTCMKTS:FSNUY) Shares Gap Up - Should You Buy?
October 2 at 7:21 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31078655
Fresenius Acquires Remaining 45% Stake In MAbxience For Up To EUR 750 Mln
October 1 at 7:37 AM  |  rttnews.comhttps://www.rttnews.com/3695605/fresenius-acquires-remaining-45-stake-in-mabxience-for-up-to-eur-750-mln.aspx
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
October 3 at 1:00 AM  |  Chaikin Analytics (Ad)
Fresenius SE Takes Full Ownership of Biosimilars Platform mAbxience
October 1 at 7:37 AM  |  marketscreener.comM
Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Large Increase in Short Interest
October 1 at 6:41 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31073837
Waltz Health and Fresenius Kabi Expand Direct Access to Biosimilars Through Waltz Connect Platform
September 29, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/waltz-health-and-fresenius-kabi-expand-direct-access-to-biosimilars-through-waltz-connect-platform-302892345.html
See More Fresenius SE & Co. Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fresenius SE & Co.? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fresenius SE & Co. and other key companies, straight to your email.

About Fresenius SE & Co.

Fresenius SE & Co. (OTCMKTS:FSNUY) KGaA is a German healthcare company headquartered in Bad Homburg, Germany. The group develops and provides products and services for hospitals, outpatient care providers and patients, with operations focused primarily on healthcare products and hospital services.

Its Fresenius Kabi business supplies medicines and technologies used in infusion therapy, clinical nutrition and transfusion medicine. Its portfolio includes intravenous drugs, generic medicines, biosimilars, infusion systems, medical devices and products for parenteral and enteral nutrition.

Fresenius also operates hospitals through Helios, which manages acute-care and rehabilitation facilities in Germany and hospitals and other healthcare services in Spain through the Quirónsalud network. The company traces its origins to a pharmacy established by Dr. Eduard Fresenius in Frankfurt in 1912. Michael Sen has served as chief executive officer since 2022.

View Fresenius SE & Co. Profile
Earnings Tools